文献速递骨质疏松与代谢性骨病

钠-葡萄糖转运体2抑制剂联合二甲双胍治疗2型糖尿病与骨折风险的关联:随机对照试验的荟萃分析

Association between combined treatment with SGLT2 inhibitors and metformin for type 2 diabetes mellitus on fracture risk: a meta-analysis of randomized controlled trials.
PubMed 文献 · Osteoporos Int · 2020-08-11

本研究纳入25项随机对照试验共19500例2型糖尿病患者,分析SGLT2抑制剂联合二甲双胍对骨折风险的影响。结果显示联合治疗组骨折88例,对照组79例,联合治疗与二甲双胍单药或其他对照相比未影响骨折风险(OR=0.97,95%CI 0.71-1.32),按药物类型、随访时间、对照方案和骨折类型分层后结果仍稳定。

要点

  • SGLT2抑制剂联合二甲双胍与二甲双胍单药或其他对照相比未影响2型糖尿病患者的骨折风险(OR=0.97,95%CI 0.71-1.32)。
  • 共纳入25项RCT、19500例2型糖尿病患者,联合治疗组骨折88例,对照组79例。
  • 按药物类型、随访时间、对照方案和骨折类型分层后,结果仍稳定。

核心结论

  • SGLT2抑制剂联合二甲双胍治疗与二甲双胍单药或其他对照相比未影响2型糖尿病患者的骨折风险(OR=0.97,95%CI 0.71-1.32)。

研究设计与样本

  • 检索PubMed、Embase、ClinicalTrials.gov和Cochrane Library数据库筛选符合条件的随机对照试验,共纳入25项RCT、19500例2型糖尿病患者,使用Review Manager 5.3软件计算汇总OR及95%CI。

主要发现

  • 联合治疗组骨折88例,对照组骨折79例。
  • SGLT2抑制剂联合二甲双胍与二甲双胍单药或其他对照相比未影响骨折风险(OR=0.97,95%CI 0.71-1.32)。
  • 按药物类型、随访时间、对照方案和骨折类型分层后,结果仍稳定。

关键数值与推荐

  • 联合治疗组与对照组骨折风险比较的汇总OR=0.97(95%CI 0.71-1.32)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: This study analyzed the effects of combination therapy with sodium-glucose transporter-2 inhibitors (SGLT2is) and metformin on fracture risk. Summarizing available randomized controlled trials, we found that SGLT2is combined with metformin therapy did not influence fracture risk compared with metformin monotherapy or other comparators in patients with T2DM. INTRODUCTION: No study is available evaluating the association between sodium-glucose transporter-2 inhibitors (SGLT2is) in combination with metformin use and fracture risk. Our study aimed to investigate the fracture risk of combination therapy with SGLT2is and metformin in patients with type 2 diabetes mellitus (T2DM). METHODS: PubMed, Embase, ClinicalTrials.gov site, and the Cochrane Library databases were scrutinized for all eligible randomized controlled trials (RCTs). The summarized odds ratios (ORs) and their 95% confidence intervals (CI) were calculated using Review Manager 5.3 software. RESULTS: A total of 25 RCTs involving 19,500 participants with T2DM were included in our studies. There were 88 fracture cases in the SGLT2is in combination with metformin therapy group and 79 in the control group. SGLT2is combined with metformin use did not influence fracture risk compared with metformin monotherapy or other comparators in patients with T2DM (OR = 0.97, 95% CI 0.71-1.32). After stratification by drug type, follow-up time, control regimen, and type of fracture, the upshots were still stable. CONCLUSION: SGLT2is and metformin combination therapy did not influence fracture risk compared with metformin monotherapy or other comparators in patients with T2DM. PROSPERO REGISTRATION NUMBER: CRD42020168435.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Qian BB, Chen Q, Li L, et al. Association between combined treatment with SGLT2 inhibitors and metformin for type 2 diabetes mellitus on fracture risk: a meta-analysis of randomized controlled trials. Osteoporos Int. 2020. PMID: 32780153. doi:10.1007/s00198-020-05590-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。